Search results Search for: Search Refine your results by duration: Any Under 5 mins Under 20 mins Over 20 mins Sort by: Relevance Views Date The dangers of using a laboratory developed test as a companion diagnostic Keith Miller, FIBMS, Director, UKNEQAS-ICC&ISH Companion diagnostic tests are most commonly used to determine patient eligibility for specific therapies and are designed to ensure the therapy is ad... 7 years ago | 51 mins Key Notables on IHC Interpretation of PD-L1 SP263 on FNA samples Dr. Dorothy Hayden, Pathologist, Companion Diagnostic, at Roche Tissue Diagnostics Dr. Dorothy Hayden, Staff Pathologist, Companion Diagnostics with Roche Tissue Diagnostics, will discuss key insights that can be applied to successfu... 2 years ago | 40 mins The Dangers of Using a Laboratory-Developed Test as a Companion Diagnostic Keith Miller, FIBMS The Dangers of Using a Laboratory-Developed Test as a Companion Diagnostic presented by Keith Miller, FIBMS, Director, UK National External Quality As... 4 years ago | 25 mins Part 2: Tumor heterogeneity and immuno-oncology Tom Grogan, MD, Founder, Senior Vice President, Ventana Medical Systems Inc. View two new CDx Insights videos “Part 1: CDx, IHC and tumor heterogeneity” and “Part 2: Tumor heterogeneity and immuno-oncology” with Tom Grogan, MD,... 6 years ago | 2 mins Companion diagnostics and targeted therapies: requirements for success Abigail McElhinny PhD, Ventana Medical Systems Inc., and Steffan Ho, MD, PhD, Pfizer Inc. Propelled by the need to personalize medical care, more and more targeted therapies and companion diagnostics are being developed. What are the key co... 7 years ago | 59 mins From biopsy to treatment: A tissue journey through pathology Zin Htway, PhD, MBAHM, CT (ASCP, IAC), Maria Magana, Danielle Westfall, MD, Los Robles Hospital and Medical Center Surgical procurement of adequate tissue can be challenging. This presentation will be an in-depth look at rapid on-site evaluation of tissue biopsies... 6 years ago | 43 mins Personalized Healthcare in Oncology: Past, Present and Future Eric Walk MD, FCAP, Chief Medical Officer, Ventana Medical Systems, Inc. Personalized healthcare continues to evolve. There are now five pillars of cancer therapy and two of the five, targeted therapies and immunotherapy, ... 7 years ago | 60 mins Part 1: CDx, IHC and tumor heterogeneity Tom Grogan, MD,Senior Vice President, Founder, Ventana Medical Systems Inc. View two new CDx Insights videos “Part 1: CDx, IHC and tumor heterogeneity” and “Part 2: Tumor heterogeneity and immuno-oncology” with Tom Grogan, MD,... 6 years ago | 4 mins
